Inovalon Holdings, Inc. (INOV): Daniel L Rizzo , other of Inovalon Holdings, Inc. sold 43,577 shares on Jul 12, 2016. The Insider selling transaction was reported by the company on Jul 13, 2016 to the Securities and Exchange Commission. The shares were sold at $20.02 per share for a total value of $872,224.56 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 13, 2016, Daniel L Rizzo (other) sold 43,577 shares at $20.02 per share price.On May 10, 2016, Keith R Dunleavy (CEO) purchased 30,000 shares at $16.39 per share price.Also, On Mar 7, 2016, Robert A Wychulis (President) sold 33,003 shares at $18.17 per share price.On Dec 7, 2015, Shauna L Vernal (Chief Legal Officer) sold 33,437 shares at $18.55 per share price.
Inovalon Holdings Inc: On Monday, Jul 11, 2016 heightened volatility was witnessed in Inovalon Holdings Inc which led to swings in the share price. The shares opened for trading at $19 and hit $19.65 on the upside , eventually ending the session at $19.62, with a gain of 2.08% or 0.4 points. The heightened volatility saw the trading volume jump to 4,98,599 shares. The 52-week high of the share price is $27.375 and the company has a market cap of $2,989 M . The 52-week low of the share price is at $15.1201.
Company has been under the radar of several Street Analysts.Inovalon Holdings Inc is Downgraded by Robert W. Baird to Neutral while Lowering the Price Target of the company shares to $ 21 from a previous price target of $22 . Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on Apr 21, 2016.
Inovalon Holdings Inc. is a technology company. The Company combines advanced cloud-based data analytics and data-driven intervention platforms to provide services for health plans hospitals physicians patients pharmaceutical companies and researchers. Through its datasets integration technologies predictive analytics and subject matter expertise the Company delivers platforms. Its analytics identify gaps in care quality data integrity and financial performance while providing clients with capabilities to resolve these gaps. The Company’s data analytics and intervention platforms consist of four primary components: data integration advanced analytics intervention platforms and business processing. This system manages the process of defining and configuring industry data feeds from its clients and partners including electronic health records laboratory pharmacy patient reported claims paper based medical records biometric and hospital data feeds.